AstraZeneca PLC (AZN)vsGrifols SA ADR (GRFS)
AZN
AstraZeneca PLC
$185.78
+0.93%
HEALTHCARE · Cap: $284.63B
GRFS
Grifols SA ADR
$7.71
+1.45%
HEALTHCARE · Cap: $7.65B
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 681% more annual revenue ($58.74B vs $7.52B). AZN leads profitability with a 17.4% profit margin vs 5.0%. GRFS appears more attractively valued with a PEG of 0.23. GRFS earns a higher WallStSmart Score of 71/100 (B).
AZN
Strong Buy66
out of 100
Grade: B-
GRFS
Strong Buy71
out of 100
Grade: B
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+32.8%
Fair Value
$306.07
Current Price
$185.78
$120.29 discount
Margin of Safety
+68.8%
Fair Value
$29.48
Current Price
$7.71
$21.77 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Earnings expanding 53.9% YoY
Every $100 of equity generates 23 in profit
Strong operational efficiency at 21.6%
Generating 1.4B in free cash flow
Growing faster than its price suggests
Reasonable price relative to book value
Attractively priced relative to earnings
Strong operational efficiency at 20.4%
Areas to Watch
Moderate valuation
4.1% revenue growth
Distress zone — elevated risk
4.0% revenue growth
ROE of 5.9% — below average capital efficiency
5.0% margin — thin
Elevated debt levels
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, EPS Growth, Return on Equity. Profitability is solid with margins at 17.4% and operating margin at 21.6%.
Bull Case : GRFS
The strongest argument for GRFS centers on PEG Ratio, Price/Book, P/E Ratio. PEG of 0.23 suggests the stock is reasonably priced for its growth.
Bear Case : AZN
The primary concerns for AZN are P/E Ratio, Revenue Growth, Altman Z-Score.
Bear Case : GRFS
The primary concerns for GRFS are Revenue Growth, Return on Equity, Profit Margin. Debt-to-equity of 1.87 is elevated, increasing financial risk. Thin 5.0% margins leave little buffer for downturns.
Key Dynamics to Monitor
GRFS carries more volatility with a beta of 1.19 — expect wider price swings.
AZN is growing revenue faster at 4.1% — sustainability is the question.
AZN generates stronger free cash flow (1.4B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
GRFS scores higher overall (71/100 vs 66/100). AZN offers better value entry with a 32.8% margin of safety. Both earn "Strong Buy" and "Strong Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Grifols SA ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Grifols, SA is dedicated to obtaining, manufacturing, preparing and selling therapeutic products, mainly blood derivatives. The company is headquartered in Barcelona, Spain.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?